Israeli Placenta-based Cell Therapy for COVID-19 Moved into Clinical Trial
source: pixabay.com

Israeli Placenta-based Cell Therapy for COVID-19 Moved into Clinical Trial

As originally shared in Tech Startups, an Israeli biotech company called Pluristem has created a placenta-based cell therapy to treat patients with COVID-19. So far, the therapy, which uses PLacental…

Continue Reading Israeli Placenta-based Cell Therapy for COVID-19 Moved into Clinical Trial
Stem Cell Therapy Using Patient’s Own Cells Shows Potential for Chronic Granulomatous Disease
source: pixabay.com

Stem Cell Therapy Using Patient’s Own Cells Shows Potential for Chronic Granulomatous Disease

Chronic granulomatous disease (CGD) is a rare form of immunodeficiency. The most common form of this disease is X-linked chronic granulomatous disease (X-CGD) which is caused by a mutated CYBB gene. This…

Continue Reading Stem Cell Therapy Using Patient’s Own Cells Shows Potential for Chronic Granulomatous Disease
The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
source: pixabay.com

The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease

According to a story from Business Wire, the biopharmaceutical company Bristol-Myers Squibb has recently announced that the US Food and Drug Administration (FDA) has granted the company's drug abatacept (marketed…

Continue Reading The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial
source: pixabay.com

First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial

According to a story from Myeloma Research News, the first patient has been dosed with an experimental allogeneic (donor derived) CAR-T cell therapy called UCARTCS1 as part of a phase…

Continue Reading First Patient Dosed with Experimental Treatment for Multiple Myeloma in Clinical Trial

Phase 3 Trial for Graft Versus Host Disease to Finally Begin After Funding Boost

Background Novartis ended all of their gene therapy programs which were oncology related in 2016. Unfortunately, that meant an end to many programs that still had potential. This included cell…

Continue Reading Phase 3 Trial for Graft Versus Host Disease to Finally Begin After Funding Boost

Phase 1b Trial for Lupus Nephritis Utilizing New Therapeutic Approach to Commence Soon

Lupus Nephritis Lupus nephritis (LN) is one of the most common complications of systemic lupus erythematosus (SLE). It affects approximately 100,000 patients in the United States alone. Basically, the patient's…

Continue Reading Phase 1b Trial for Lupus Nephritis Utilizing New Therapeutic Approach to Commence Soon

Analysis of Phase 3 Study Shows Inolimomab has Long-term Clinical Benefit for Graft-Versus-Host-Disease

About Graft-Versus-Host-Disease (GvHD) Graft-Versus-Host-Disease (GvHD) occurs when a patient's body rejects cells which have been transplanted. For instance, it may develop following a stem cell transplant or a bone marrow transplant. The…

Continue Reading Analysis of Phase 3 Study Shows Inolimomab has Long-term Clinical Benefit for Graft-Versus-Host-Disease
Researchers Announce Positive Results From a Phase I Study of a Therapy For Acute GvHD
stevepb / Pixabay

Researchers Announce Positive Results From a Phase I Study of a Therapy For Acute GvHD

Cynata Therapeutics, an Australian stem cell and regenerative medicine company, has announced positive results from a Phase 1 clinical trial of CYP-001, the CymerusTM mesenchymal stem cell product candidate. The study…

Continue Reading Researchers Announce Positive Results From a Phase I Study of a Therapy For Acute GvHD
Kalytera Therapeutics Will Meet with the FDA to Discuss Cannabidiol as a Possible Treatment For Acute GVHD
889520 / Pixabay

Kalytera Therapeutics Will Meet with the FDA to Discuss Cannabidiol as a Possible Treatment For Acute GVHD

Kalytera Therapeutics, Inc. has announced that a meeting with the Centre for Drug Evaluation and Research of the US FDA is planned for Tuesday, 31st July this year. The purpose of…

Continue Reading Kalytera Therapeutics Will Meet with the FDA to Discuss Cannabidiol as a Possible Treatment For Acute GVHD
ICYMI: New Investigational Treatment Could be a Step Forward Against Graft-versus-Host Disease
source: pixabay.com

ICYMI: New Investigational Treatment Could be a Step Forward Against Graft-versus-Host Disease

According to a story from Financial Buzz, the pharmaceutical company Elsayls Biotech is planning to submit a proposal to the European Medicines Agency (EMA) in order to conduct a clinical…

Continue Reading ICYMI: New Investigational Treatment Could be a Step Forward Against Graft-versus-Host Disease
A Boy Survived His Leukemia Only To Face The Dangers of Graft Versus Host Disease
source: pixabay.com

A Boy Survived His Leukemia Only To Face The Dangers of Graft Versus Host Disease

According to a story from wqad.com, transplants are responsible for saving thousands of lives. Often, transplants are the last resort in diseases that have become to severe to treat effectively.…

Continue Reading A Boy Survived His Leukemia Only To Face The Dangers of Graft Versus Host Disease
Close Menu